Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969459 | 0.91 | DPP4 (0.54) | DPP4CHRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL3970827 | 0.91 | DPP4 (0.47) | DPP4CHRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL3971099 | 0.89 | DPP4 (0.52) | DPP4CHRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL3966412 | 0.89 | DPP4 (0.47) | DPP4CHRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL3972356 | 0.88 | DPP4 (0.48) | DPP4CHRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL3973731 | 0.88 | DPP4 (0.50) | DPP4CHRM1 | |
| SCHEMBL3977495 | 0.84 | DPP4 (0.49) | DPP4CHRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL3972010 | 0.84 | DPP4 (0.55) | DPP4CHRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL3966158 | 0.83 | DPP4 (0.49) | DPP4CHRM1KCNH2CHRM2CHRM3 | |
| SCHEMBL4232434 | 0.82 | DPP4 (0.54) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569574-B2 | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-08-04 | — | — | US | disclosed |
| EP-1532150-B1 | NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1532150-A1 | NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
| WO-2004018469-A1 | NOVEL PURINE DERIVATIVES, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | DPP4 1/4885CHRM1 1289/4885KCNH2 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.